The escalating cost of biologic therapies presents a significant challenge to healthcare system sustainability and patient access globally. Biosimilars offer a viable solution by providing comparable efficacy and safety at a reduced cost, thereby enhancing the affordability and availability of essential treatments. This review highlights the role of biosimilars in achieving healthcare sustainability, drawing insights from China's evolving regulatory landscape and approval trends.
Biosimilars represent a critical strategy for improving access to high-cost biologics and ensuring the sustainability of healthcare systems worldwide.1 Over the past decade, China has transitioned from a nascent market to one of the most active regions for biosimilar development.1 This transformation has been driven by an evolving regulatory framework, which began with the foundational 2015 Technical Guidelines and has matured into a current system comprising 19 technical and product-specific guidelines.1 This framework emphasizes a stepwise, science-driven comparability paradigm, aligning with international regulatory standards.1
Approval Dynamics and Global Integration
A systematic analysis of 83 biosimilars approved between 2019 and 2025 in China illustrates trends across molecular classes, therapeutic areas, and regulatory review pathways.1 This analysis demonstrates the evolution of regulatory expectations and sponsor development strategies through representative case examples.1 The increasing number of biosimilar approvals is also emphasized in the 2025 annual reports from both the US Food and Drug Administration and the European Medicines Agency, providing a comparative context for China's experience.1
China's expanding biosimilar development pipeline is particularly relevant in the context of the forthcoming global biologics patent cliff and ongoing international initiatives aimed at streamlining biosimilar development.1 This trend highlights China's increasing integration into the global biopharmaceutical landscape.1 The development and adoption of biosimilars are essential for managing healthcare expenditures and ensuring that patients have access to necessary biologic therapies, thereby contributing to the long-term sustainability of healthcare systems.1
The increasing availability and regulatory alignment of biosimilars, particularly evidenced by China's rapid expansion in this sector, present a clear directive for clinical practice. For general practitioners and specialists, understanding the comparability data and regulatory pathways of biosimilars is no longer optional; it is essential for informed prescribing decisions. The economic benefits of biosimilars are substantial, offering a mechanism to alleviate the financial burden of high-cost biologics on healthcare systems and, by extension, on patients. This allows for broader patient access to treatments that might otherwise be prohibitively expensive, directly impacting health equity.
The industry's focus on biosimilar development, as seen in China's robust pipeline and integration into the global biopharmaceutical landscape, signals a sustained shift. Pharmaceutical companies that invest in biosimilar research and development are not merely responding to market demand; they are actively contributing to a more sustainable healthcare ecosystem. This trend should encourage healthcare providers to engage with pharmaceutical representatives to understand the specific biosimilar options available and their evidence base, ensuring that cost-effectiveness does not compromise patient outcomes.
Ultimately, the move towards biosimilars is a pragmatic approach to resource allocation within healthcare. It allows for the reallocation of funds to other critical areas of patient care, research, and infrastructure. Clinicians have a role in advocating for and adopting these therapies where appropriate, thereby supporting both individual patient needs and the broader financial health of the healthcare system. The evidence from regulatory bodies like the FDA and EMA, alongside China's experience, reinforces that biosimilars are not merely alternatives but integral components of modern therapeutic strategies.
- The Pivot Biosimilars are crucial for improving access to high-cost biologics and ensuring healthcare system sustainability.
- The Data China approved 83 biosimilars between 2019 and 2025, demonstrating a maturing regulatory framework.
- The Action Clinicians should consider biosimilar options to support healthcare system sustainability and patient access to biologics.
ART-2026-406
06/26
Cite This Article
Team TLSFE. Biosimilars: a sustainable strategy for healthcare systems. The Life Science Feed. Updated June 17, 2026. Accessed June 17, 2026. https://thelifesciencefeed.com/healthcare-sys-and-biz/health-policy/insights/biosimilars-a-sustainable-strategy-for-healthcare-systems.
Editorial & AI Standards
All content is researched from peer-reviewed, open-access sources — published trial data, clinical guidelines, and regulatory filings. AI tools are used solely to structure and summarise that evidence; no AI-generated conclusions appear without editor verification against the primary source.
Every article is reviewed by a named editor before publication. Source citations are listed in the References section. This content does not represent the views of any pharmaceutical company, medical device manufacturer, or healthcare provider.
Licence & Rights
© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.
Medical Disclaimer
The information provided on The Life Science Feed is for educational and informational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider regarding any medical condition or treatment decision. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
References
1. Yang M, Zhang N, Wang H. An Overview and Trend Analysis of Biosimilar Approvals in China. BioDrugs. 2026;42307859.
